Johnson & Johnson $JNJ Shares Sold by FourThought Financial Partners LLC

FourThought Financial Partners LLC decreased its position in Johnson & Johnson (NYSE:JNJ) by 6.5% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 15,533 shares of the company’s stock after selling 1,085 shares during the period. FourThought Financial Partners LLC’s holdings in Johnson & Johnson were worth $2,373,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in the business. Clark Asset Management LLC boosted its holdings in Johnson & Johnson by 51.6% during the 2nd quarter. Clark Asset Management LLC now owns 8,884 shares of the company’s stock valued at $1,357,000 after acquiring an additional 3,025 shares during the period. Apexium Financial LP increased its stake in Johnson & Johnson by 10.7% during the first quarter. Apexium Financial LP now owns 23,989 shares of the company’s stock worth $3,978,000 after purchasing an additional 2,310 shares during the period. Avanza Fonder AB lifted its position in shares of Johnson & Johnson by 2.9% during the second quarter. Avanza Fonder AB now owns 234,647 shares of the company’s stock worth $35,842,000 after purchasing an additional 6,566 shares in the last quarter. Tokio Marine Asset Management Co. Ltd. boosted its stake in shares of Johnson & Johnson by 7.0% in the first quarter. Tokio Marine Asset Management Co. Ltd. now owns 73,350 shares of the company’s stock valued at $12,164,000 after purchasing an additional 4,816 shares during the period. Finally, Klingman & Associates LLC grew its holdings in shares of Johnson & Johnson by 13.4% in the first quarter. Klingman & Associates LLC now owns 16,984 shares of the company’s stock valued at $2,817,000 after purchasing an additional 2,005 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the business’s stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the transaction, the executive vice president owned 178,013 shares in the company, valued at $31,652,491.53. The trade was a 24.08% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. 0.16% of the stock is currently owned by corporate insiders.

Johnson & Johnson Trading Up 1.1%

Shares of Johnson & Johnson stock opened at $206.07 on Tuesday. The company has a current ratio of 1.07, a quick ratio of 0.80 and a debt-to-equity ratio of 0.50. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $206.94. The stock has a market cap of $496.48 billion, a price-to-earnings ratio of 19.89, a PEG ratio of 2.19 and a beta of 0.38. The company has a fifty day simple moving average of $188.83 and a 200-day simple moving average of $172.13.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. The business had revenue of $24.02 billion for the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%. On average, equities analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th will be given a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 2.5%. The ex-dividend date of this dividend is Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 50.19%.

Wall Street Analysts Forecast Growth

Several brokerages have commented on JNJ. Royal Bank Of Canada reissued an “outperform” rating and issued a $209.00 price target on shares of Johnson & Johnson in a research report on Friday, October 10th. JPMorgan Chase & Co. increased their price objective on Johnson & Johnson from $185.00 to $200.00 and gave the company a “neutral” rating in a research note on Tuesday, September 16th. Argus set a $210.00 target price on Johnson & Johnson in a research note on Wednesday, October 15th. Cowen restated a “buy” rating on shares of Johnson & Johnson in a report on Tuesday, October 14th. Finally, Wall Street Zen upgraded Johnson & Johnson from a “hold” rating to a “buy” rating in a research note on Saturday, September 13th. Four research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat.com, Johnson & Johnson currently has an average rating of “Moderate Buy” and a consensus price target of $201.05.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.